- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | GET MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 530.65 0.63% | 531.85 1.30% | More Info
|
|
| AJANTA PHARMA | 987.15 -0.81% | 986.00 -1.11% | More Info
|
|
| ALEMBIC PHARMA | 516.35 -0.62% | 517.05 -0.63% | More Info
|
|
| BIOCON LTD | 584.95 -1.28% | 584.80 -1.15% | More Info
|
|
| CADILA HEALTHCARE | 354.10 -1.50% | 354.25 -1.64% | More Info
|
|
| CIPLA | 627.15 -1.63% | 627.40 -1.58% | More Info
|
|
| DIVIS LABORATORIES | 1,085.45 1.05% | 1,085.20 0.98% | More Info
|
|
| GLENMARK PHARMA | 554.70 -1.49% | 555.75 -1.46% | More Info
|
|
| INDOCO REMEDIES | 175.75 -1.54% | 175.25 -2.31% | More Info
|
|
| IPCA LABS | 739.35 -0.35% | 742.00 -0.24% | More Info
|
|
| J.B.CHEMICALS | 261.95 1.16% | 260.05 -0.19% | More Info
|
|
| LUPIN LTD | 809.80 -2.23% | 811.00 -1.98% | More Info
|
|
| NATCO PHARMA | 778.20 -0.99% | 779.25 -1.26% | More Info
|
|
| NIFTY 50 | Not Listed | 10,980.45 -0.25% | More Info
|
|
| ORCHID PHARMA LTD | 6.97 -2.92% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 221.30 0.50% | 219.15 -1.35% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,558.45 1.31% | 2,560.40 1.15% | More Info
|
|
| S&P BSE SENSEX | 36,373.44 -0.40% | Not Listed | More Info
|
|
| STRIDES SHASUN LTD | 353.00 -2.03% | 352.55 -2.07% | More Info
|
|
| SUN PHARMA | 549.55 0.14% | 549.90 0.23% | More Info
|
|
| TORRENT PHARMA | 1,440.65 -0.77% | 1,441.65 -0.55% | More Info
|
|
| WOCKHARDT LTD. | 577.30 -2.84% | 576.50 -2.82% | More Info
|
BSE prices: July 18, 2018 (Close) NSE prices: July 18, 2018 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 8,885.7 (down 0.5%). The index is down 4.7% over the last 30 days. And over the last 1 year, it has lost 11.4%.
Within the Indian Pharma sector, the top gainers were PIRAMAL ENTERPRISES (up 1.3%) and J.B.CHEMICALS (up 1.2%). On the other hand, ORCHID PHARMA LTD (down 2.9%) and WOCKHARDT LTD. (down 2.8%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,980.5 (down 0.3%).
|
| |
Today's Market
Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)
Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.
Related Views on News
PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%
Jun 20, 2018 | Updated on Jun 20, 2018For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3%
Jun 19, 2018 | Updated on Jun 19, 2018For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%
Jun 1, 2018 | Updated on Jun 1, 2018For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
More Views on NewsMost Popular
How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)
Jul 12, 2018Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)
Jul 11, 2018The price signals that MSP sends out, creates its own set of problems.
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
More|
| |
S&P BSE HEALTHCARE
Jul 18, 2018 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.